Conditions: Non-Ischemic Central Retinal Vein Occlusion
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 68
Healthy volunteers: yes

Brief summary:
This is a study designed to determine if the addition of Ozurdex® to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.

Detailed description:
This is a multicenter clinical study designed to determine if the addition of Ozurdex® injection to bevacizumab (Avastin®) eye injections reduces the need for repeat bevacizumab eye injections in patients with nonischemic central retina vein occlusion.

Arms:
arm 1: Active bevacizumab (Avastin®) and Sham Ozurdex® arm 2: Active bevacizumab (Avastin®) and Active Ozurdex®

Interventions: intervention 1: Active bevacizumab and Sham dexamethasone intervention 2: Active bevacizumab and Active dexamethasone
Intervention descriptions: intervention 1: Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe intervention 2: Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose

Protocol document: